-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Insiders Who Placed Huge Bets on C-MER Eye Care Holdings Limited (HKG:3309) Earlier This Year Would Be Disappointed With the 8.8% Drop
Insiders Who Placed Huge Bets on C-MER Eye Care Holdings Limited (HKG:3309) Earlier This Year Would Be Disappointed With the 8.8% Drop
The recent price decline of 8.8% in C-MER Eye Care Holdings Limited's (HKG:3309) stock may have disappointed insiders who bought HK$48m worth of shares at an average price of HK$5.26 in the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth HK$33m which is not ideal.
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
See our latest analysis for C-MER Eye Care Holdings
The Last 12 Months Of Insider Transactions At C-MER Eye Care Holdings
In the last twelve months, the biggest single purchase by an insider was when Chairman & CEO Shun Chiu Lam bought HK$48m worth of shares at a price of HK$5.26 per share. That means that even when the share price was higher than HK$3.64 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Shun Chiu Lam was the only individual insider to buy during the last year.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
SEHK:3309 Insider Trading Volume September 22nd 2022There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Does C-MER Eye Care Holdings Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 1.6% of C-MER Eye Care Holdings shares, worth about HK$70m, according to our data. However, it's possible that insiders might have an indirect interest through a more complex structure. Whilst better than nothing, we're not overly impressed by these holdings.
So What Does This Data Suggest About C-MER Eye Care Holdings Insiders?
There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. Overall we don't see anything to make us think C-MER Eye Care Holdings insiders are doubting the company, and they do own shares. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 3 warning signs with C-MER Eye Care Holdings and understanding these should be part of your investment process.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
最近价格下跌了8.8%,C-mer眼科护理控股有限公司(HKG:3309)股票可能令过去12个月以5.26港元的平均价买入价值4800万港元的股票的内部人士感到失望。内部人士买入股票的预期是,他们的投资会在一段时间内升值。然而,最近的亏损使他们的上述投资价值3300万港元,这并不理想。
尽管我们不认为股东应该简单地追随内幕交易,但我们认为完全忽视内幕交易是愚蠢的。
查看我们对C-mer Eye Care Holdings的最新分析
C-mer Eye Care Holdings最近12个月的内幕交易
在过去12个月里,内部人士最大的一笔收购是董事长兼首席执行官林顺超以每股5.26港元的价格购买了价值4800万港元的股票。这意味着,即使股价高于3.64港元(最近的价格),也有内部人士想要购买股票。尽管他们的观点可能在收购后发生了变化,但这至少表明他们对公司的未来充满信心。对我们来说,考虑内部人士为股票支付的价格非常重要。看到内部人士支付高于当前股价的价格是令人鼓舞的,因为这表明他们看到了价值,即使是在更高的水平。林顺超是去年唯一买入的个人内部人士。
你可以看到过去一年的内幕交易(由公司和个人),如下图所示。通过点击下面的图表,你可以看到每一笔内幕交易的准确细节!
联交所:3309内幕交易量2022年9月22日内部人士总是在买入大量股票。因此,如果这适合你的风格,你可以逐一检查每一种库存,或者你可以看看这个免费公司名单。(提示:内部人士一直在买入这些股票)。
C-mer Eye Care Holdings是否拥有很高的内部人持股?
对于一个普通股股东来说,公司内部人士持有多少股份值得一查。内部人持股比例较高往往会让公司领导层更加关注股东利益。根据我们的数据,内部人士持有C-mer Eye Care Holdings 1.6%的股份,价值约7000万港元。然而,内部人士可能会通过更复杂的结构拥有间接利益。虽然总比什么都没有好,但我们对这些持股并不是太印象深刻。
那么,这些数据对C-mer眼科护理控股公司的内部人士有何启示?
过去三个月没有发生任何内幕交易--这并不意味着什么。乐观的一面是,过去一年的交易令人鼓舞。总体而言,我们没有看到任何让我们认为C-mer Eye Care Holdings的内部人士对该公司持怀疑态度的东西,他们确实持有该公司的股份。因此,虽然了解内部人士在买入或卖出方面做了什么是有帮助的,但了解一家特定公司面临的风险也是有帮助的。在投资风险方面,我们已经确定了三个警告信号与C-mer眼科护理控股公司合作,并了解这些应该是您投资过程的一部分。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费列出了一些有趣的公司,这些公司拥有高股本回报率和低债务。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧